Andrew Huberman· PhD
Another one we should talk about at a subsequent time is 17 Alpha estradiol this continues to work in male mice and it produces comparable effects to rapamycin
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Another one we should talk about at a subsequent time is 17 Alpha estradiol this continues to work in male mice and it produces comparable effects to rapamycin
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so that means of the drugs that we've tested for late start rapamycin works perfectly a carbos works about half half as well as an early start and 17 alpha ester dial seems to work just as well in late middle age
there are changes with rapamycin both males and females there are changes with a carbos both males and females and their changes with 17 alpha estradiol but it's the males only and that's really cool because it's the males only that get a life span benefit from 17 alphestra dial
and the original dose of rapamycin is there or slightly below that we now have a better result with rapamycin when we combine it with a carbos we can kick the male lifespan up to 29% increase unbelievable that's our that's our winner
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.